-
Antiviral API
- Arenavirus
- Cytomegalovirus (CMV)
- Dengue virus
- Endogenous Metabolite
- Enterovirus (EV)
- Epstein-Barr virus (EBV)
- Filovirus
- Flavivirus
- HCV Protease
- Hepatitis B Virus (HBV)
- Hepatitis C Virus (HCV)
- Herpes simplex Virus (HSV)
- HIF/HIF Prolyl-Hydroxylase
- HIV Integrase
- HIV Protease
- Human immunodeficiency Virus (HIV)
- Human papillomavirus (HPV)
- Influenza Virus
- Nipah virus
- Orthopoxvirus
- Others
- Rabies virus (RABV)
- Respiratory syncytial Virus (RSV)
- Reverse Transcriptases (RTs)
- SARS-CoV
- Tobacco mosaic virus (TMV)
- Vesicular stomatitis virus (VSV)
- Virus Protease
- West Nile virus
- Antiviral intermediates
ITX-5061 HCl
![{PARAM:[Name]}({[CAS]})](https://resource.bocsci.com/structure/1252679-52-9.gif)
| Category | Hepatitis C Virus (HCV) |
| CAS | 1252679-52-9 |
| Description | This active molecular is a scavenger receptor B1 antagonist under the development by iTherX Pharmaceuticals for the treatment of Hepatitis C. ITX-5061 shows a special mechanism of action that prevents the hepatitis C virus from entering liver cells. Preclinical studies have shown that ITX-5061 can prevent virus binding/fusion and cell to cell spread. In Jan 2015, Phase-II clinical trials in Hepatitis C in USA was on-going. |
Product Information
| Synonyms | ITX-5061; ITX 5061; ITX5061; UNII-J4RA8K2Q2A; J4RA8K2Q2A;CHEMBL3402567;N-[5-tert-butyl-3-(methanesulfonamido)-2-methoxyphenyl]-2-[4-(2-morpholin-4-ylethoxy)naphthalen-1-yl]-2-oxoacetamide;hydrochloride;848144-15-0 (free base) |
| IUPAC Name | N-[5-tert-butyl-3-(methanesulfonamido)-2-methoxyphenyl]-2-[4-(2-morpholin-4-ylethoxy)naphthalen-1-yl]-2-oxoacetamide;hydrochloride |
| Molecular Weight | 620.16 |
| Molecular Formula | C30H38ClN3O7S |
| Canonical SMILES | CC(C)(C)C1=CC(=C(C(=C1)NS(=O)(=O)C)OC)NC(=O)C(=O)C2=CC=C(C3=CC=CC=C32)OCCN4CCOCC4.Cl |
| InChI | InChI=1S/C30H37N3O7S.ClH/c1-30(2,3)20-18-24(28(38-4)25(19-20)32-41(5,36)37)31-29(35)27(34)23-10-11-26(22-9-7-6-8-21(22)23)40-17-14-33-12-15-39-16-13-33;/h6-11,18-19,32H,12-17H2,1-5H3,(H,31,35);1H |
| InChIKey | ICIJBYYMEBOTQP-UHFFFAOYSA-N |
| Purity | 98% |
| Solubility | Soluble in DMSO |
| Appearance | Powder |
| Application | Hepatitis C |
| Shelf Life | 2 month in rt, long time |
| Storage | -20°C Freezer |
| Complexity | 989 |
| Exact Mass | 619.2118994 |
| In Vitro | ITX5061 is a type II inhibitor of p38 MAPK and also an antagonist of scavenger receptor B1 (SR-B1). Treatment of ITX5061 (30 mg/kg/day) for mice results in a 50% increase in HDL-C levels compare to baseline. ApoA-I levels are moderately (+15 %) but significantly increased in ITX5061-treated HuAITg mice, compare to mice receive vehicle. ITX5061 significantly decreases HDL-CE catabolism with an FCR of 1.86±0.40 pools/d vs 2.47±0.26 pools/d in the control group (P<0.05), while calculated production rates are identical in both groups (129±24 μg/g/d vs 129±16 μg/g/d). Moreover, accumulation of [3H] CE in the liver is significantly lower in ITX5061-treated mice indicating that increased HDL-CE levels are due to reduced uptake by the liver. |
| PSA | 135.14000 |
| Target | p38 MAPK; Autophagy; HCV |